Stock BFRI BIOFRONTERA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Biofrontera Inc.

Equities

BFRI

US09077D2099

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
1.66 USD +11.04% Intraday chart for Biofrontera Inc. -2.92% -40.07%
Mar. 18 Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024
Mar. 15 Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Business Summary

Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.

Number of employees: 84

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
29 100.0 % 34 100.0 % +18.82%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
29 100.0 % 34 100.0 % +18.82%

Managers

Managers TitleAgeSince
Hermann Lübbert CEO
 Chief Executive Officer 68 15-02-28
Fred Leffler DFI
 Director of Finance/CFO 41 22-10-23
Erica Gates DFI
 Director of Finance/CFO - 19-07-31
Jon Lyons CTO
 Chief Tech/Sci/R&D Officer - 21-09-30
Alycia Torres ADM
 Chief Administrative Officer - 22-09-30
Daniel Hakansson CMP
 Compliance Officer - 18-12-31
Samantha Widdicombe
- -
Mark Baldyga SAM
 Sales & Marketing - 16-04-30

Members of the board

Members of the board TitleAgeSince
John Borer BRD
 Director/Board Member 67 21-11-01
Hermann Lübbert CEO
 Chief Executive Officer 68 15-02-28
Kevin D. Weber BRD
 Director/Board Member 66 22-03-01
Heikki Lanckriet BRD
 Director/Board Member 47 23-07-11
Beth J. Hoffman BRD
 Director/Board Member 68 15-03-02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 5,089,413 3,595,628 ( 70.65 %) 0 70.65 %

Shareholders

NameEquities%Valuation
Laurence Lytton
9.910 %
504,337 9.910 % 776 679 $
Rosalind Advisors, Inc.
9.908 %
504,261 9.908 % 776 562 $
Michael Bigger
9.878 %
502,754 9.878 % 774 241 $
AIGH Capital Management LLC
9.852 %
501,434 9.852 % 772 208 $
BIOFRONTERA AG
7.859 %
400,000 7.859 % 616 000 $
Armistice Capital LLC
3.303 %
168,105 3.303 % 258 882 $
Matejka & Partner Asset Management GmbH
0.8449 %
43,000 0.8449 % 66 220 $
Hermann Lübbert
0.2051 %
10,440 0.2051 % 16 078 $
amandea Vermögensverwaltung AG
0.1964 %
9,996 0.1964 % 15 394 $
Erica Monaco
0.1307 %
6,651 0.1307 % 10 243 $
NameEquities%Valuation
Bard Associates, Inc.
-
187,900 - 12 777 $
G1 Execution Services LLC
-
17,381 - 1 182 $
Clear Street LLC
-
10,889 - 740 $
Woodbury Financial Services, Inc.
-
1,709 - 116 $
U.S. Bank Main Branch (363657)
-
1,000 - 68 $
UBS Securities LLC
-
210 - 14 $
BofA Securities, Inc.
-
111 - 8 $

Holdings

NameEquities%Valuation
BIOFRONTERA AG
9.97%
 6,360,146 9.97% 2,349,184 $

Company contact information

Biofrontera, Inc.

120 Presidnetial Way Suite 330

01801, Woburn

+781-245-1325

http://www.biofrontera-us.com
address Biofrontera Inc.(BFRI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings for Biofrontera Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.66 USD
Average target price
16 USD
Spread / Average Target
+863.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BIOFRONTERA INC. Stock Biofrontera Inc.
-40.07% 7.61M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.87% 570B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 321B
ABBVIE INC. Stock AbbVie Inc.
+8.28% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.09% 217B
ROCHE HOLDING AG Stock Roche Holding AG
-9.12% 204B
NOVARTIS AG Stock Novartis AG
+5.01% 199B
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BFRI Stock
  4. Company Biofrontera Inc.